333 related articles for article (PubMed ID: 28827416)
21. Antimonial drugs entrapped into phosphatidylserine liposomes: physicochemical evaluation and antileishmanial activity.
Borborema SE; Osso Junior JA; Andrade Junior HF; Nascimento Nd
Rev Soc Bras Med Trop; 2016 Apr; 49(2):196-203. PubMed ID: 27192589
[TBL] [Abstract][Full Text] [Related]
22. Decreased sensitivity to meglumine antimoniate (Glucantime) of Leishmania infantum isolated from dogs after several courses of drug treatment.
Gramiccia M; Gradoni L; Orsini S
Ann Trop Med Parasitol; 1992 Dec; 86(6):613-20. PubMed ID: 1304703
[TBL] [Abstract][Full Text] [Related]
23. Hepatotoxicity of pentavalent antimonial drug: possible role of residual Sb(III) and protective effect of ascorbic acid.
Kato KC; Morais-Teixeira E; Reis PG; Silva-Barcellos NM; Salaün P; Campos PP; Dias Corrêa-Junior J; Rabello A; Demicheli C; Frézard F
Antimicrob Agents Chemother; 2014; 58(1):481-8. PubMed ID: 24189251
[TBL] [Abstract][Full Text] [Related]
24. Two cases of visceral leishmaniasis in Colombia resistant to meglumine antimonial treatment.
Vélez ID; Colmenares LM; Muñoz CA
Rev Inst Med Trop Sao Paulo; 2009; 51(4):231-6. PubMed ID: 19739006
[TBL] [Abstract][Full Text] [Related]
25. Quantification of Leishmania infantum kinetoplast DNA for monitoring the response to meglumine antimoniate therapy in visceral leishmaniasis.
Pourabbas B; Ghadimi Moghadam A; Pouladfar G; Rezaee Z; Alborzi A
Am J Trop Med Hyg; 2013 May; 88(5):868-71. PubMed ID: 23400573
[TBL] [Abstract][Full Text] [Related]
26. In vitro susceptibility to pentavalent antimony in Leishmania infantum strains is not modified during in vitro or in vivo passages but is modified after host treatment with meglumine antimoniate.
Carrió J; Portús M
BMC Pharmacol; 2002 May; 2():11. PubMed ID: 12019027
[TBL] [Abstract][Full Text] [Related]
27. Treatment of murine visceral leishmaniasis using an 8-hydroxyquinoline-containing polymeric micelle system.
Duarte MC; Lage LM; Lage DP; Martins VT; Carvalho AM; Roatt BM; Menezes-Souza D; Tavares CA; Alves RJ; Barichello JM; Coelho EA
Parasitol Int; 2016 Dec; 65(6 Pt A):728-736. PubMed ID: 27425599
[TBL] [Abstract][Full Text] [Related]
28. Ex vivo host and parasite response to antileishmanial drugs and immunomodulators.
Gonzalez-Fajardo L; Fernández OL; McMahon-Pratt D; Saravia NG
PLoS Negl Trop Dis; 2015 May; 9(5):e0003820. PubMed ID: 26024228
[TBL] [Abstract][Full Text] [Related]
29. Cyclobenzaprine Raises ROS Levels in Leishmania infantum and Reduces Parasite Burden in Infected Mice.
Cunha-Júnior EF; Andrade-Neto VV; Lima ML; da Costa-Silva TA; Galisteo Junior AJ; Abengózar MA; Barbas C; Rivas L; Almeida-Amaral EE; Tempone AG; Torres-Santos EC
PLoS Negl Trop Dis; 2017 Jan; 11(1):e0005281. PubMed ID: 28045892
[TBL] [Abstract][Full Text] [Related]
30. High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type-1-infected patients.
Delgado J; Macías J; Pineda JA; Corzo JE; González-Moreno MP; de la Rosa R; Sánchez-Quijano A; Leal M; Lissen E
Am J Trop Med Hyg; 1999 Nov; 61(5):766-9. PubMed ID: 10586909
[TBL] [Abstract][Full Text] [Related]
31. Meglumine Antimoniate-Loaded Aqueous-Core PLA Nanocapsules: Old Drug, New Formulation against Leishmania-Related Diseases.
Cosco D; Bruno F; Castelli G; Puleio R; Bonacci S; Procopio A; Britti D; Fresta M; Vitale F; Paolino D
Macromol Biosci; 2021 Jul; 21(7):e2100046. PubMed ID: 34117834
[TBL] [Abstract][Full Text] [Related]
32. [Resistance of Leishmania infantum to Glucantime: risk factors and therapeutic management].
Piarroux R; Garnier JM; Gambarelli F; Dumon H; Kaplanski S; Unal D
Arch Pediatr; 1996 Apr; 3(4):352-6. PubMed ID: 8762958
[TBL] [Abstract][Full Text] [Related]
33. Use of topical liposomes containing meglumine antimoniate (Glucantime) for the treatment of L. major lesion in BALB/c mice.
Kalat SA; Khamesipour A; Bavarsad N; Fallah M; Khashayarmanesh Z; Feizi E; Neghabi K; Abbasi A; Jaafari MR
Exp Parasitol; 2014 Aug; 143():5-10. PubMed ID: 24780938
[TBL] [Abstract][Full Text] [Related]
34. Comparative efficacy of meglumine antimoniate and aminosidine sulphate, alone or in combination, in canine leishmaniasis.
Oliva G; Gradoni L; Cortese L; Orsini S; Ciaramella P; Scalone A; de Luna R; Persechino A
Ann Trop Med Parasitol; 1998 Mar; 92(2):165-71. PubMed ID: 9625912
[TBL] [Abstract][Full Text] [Related]
35. Serological and parasitological follow-up in dogs experimentally infected with Leishmania infantum and treated with meglumine antimoniate.
Riera C; Valladares JE; Gállego M; Aisa MJ; Castillejo S; Fisa R; Ribas N; Carrió J; Alberola J; Arboix M
Vet Parasitol; 1999 Jul; 84(1-2):33-47. PubMed ID: 10435789
[TBL] [Abstract][Full Text] [Related]
36. Oral delivery of meglumine antimoniate-beta-cyclodextrin complex for treatment of leishmaniasis.
Demicheli C; Ochoa R; da Silva JB; Falcão CA; Rossi-Bergmann B; de Melo AL; Sinisterra RD; Frézard F
Antimicrob Agents Chemother; 2004 Jan; 48(1):100-3. PubMed ID: 14693525
[TBL] [Abstract][Full Text] [Related]
37. Visceral leishmaniasis during pregnancy treated with meglumine antimoniate.
Utili R; Rambaldi A; Tripodi MF; Andreana A
Infection; 1995; 23(3):182-3. PubMed ID: 7499009
[TBL] [Abstract][Full Text] [Related]
38. Sinergism between alkaloids piperine and capsaicin with meglumine antimoniate against Leishmania infantum.
Vieira-Araújo FM; Macedo Rondon FC; Pinto Vieira ÍG; Pereira Mendes FN; Carneiro de Freitas JC; Maia de Morais S
Exp Parasitol; 2018 May; 188():79-82. PubMed ID: 29625099
[TBL] [Abstract][Full Text] [Related]
39. Oral leishmaniasis in an HIV-positive patient caused by two different zymodemes of Leishmania infantum.
Cortés P; Cardeñosa N; Romaní J; Gállego M; Muñoz C; Barrio JL; Riera C; Portús M
Trans R Soc Trop Med Hyg; 1997; 91(4):438-9. PubMed ID: 9373646
[No Abstract] [Full Text] [Related]
40. Biodistribution of meglumine antimoniate in healthy and Leishmania (Leishmania) infantum chagasi-infected BALB/c mice.
Borborema SE; Osso JA; Andrade HF; Nascimento Nd
Mem Inst Oswaldo Cruz; 2013 Aug; 108(5):623-30. PubMed ID: 23903979
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
